Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast
Legend Biotech shares fell over 10% intraday on December 8, 2025, hitting a new 52-week low of $25.66 despite reporting 75% revenue growth over the past year. UBS cut its price target to $48 but kept a Buy rating. Investors cited concerns over profitability and cash flow. The stock has dropped more than 30% year-over-year.